Transcription factor profiling shows new ways towards new treatment options of cutaneous T cell lymphomas

Udo Döbbeling1

  • 1Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. Udo.Doebbeling@usz.ch

Insights

Most oncogenes involve transcription factors. In cancer, these factors become constitutively active, driving tumor growth and apoptosis resistance. Targeting these aberrant pathways offers new anti-cancer drug strategies, particularly for cutaneous T cell lymphomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Most oncogenes encode transcription factor activators.
  • Inducible transcription factors are tightly regulated by growth stimuli.
  • Cancer cells exhibit dysregulated transcription factor activity, leading to uncontrolled growth and apoptosis resistance.

Purpose of the Study:

  • To investigate the role of transcription factors in cancer.
  • To identify aberrant signaling pathways in cutaneous T cell lymphomas.
  • To explore potential therapeutic targets for cancer treatment.

Main Methods:

  • Analysis of oncogene-encoded transcription factors.
  • Identification of constitutively active transcription factors in cancer cells.
  • Application of pathway analysis to cutaneous T cell lymphomas.

Main Results:

  • Dysregulated transcription factors are crucial in cancer progression.
  • Specific signaling pathways were identified in cutaneous T cell lymphomas.
  • Several classes of agents were identified as potential anti-cancer drugs.

Conclusions:

  • Aberrant transcription factor activity is a hallmark of cancer.
  • Targeting dysregulated pathways can inhibit cancer cell growth and survival.
  • The identified agents show promise as novel therapeutics for cutaneous T cell lymphomas.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
General Transcription Factors01:30

General Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...